New Leader for Immunobiology: Chandrashekhar Pasare, DVM, PhD
Post Date: September 7, 2023 | Publish Date:
When he begins his role on Sept. 11, Pasare will build on existing programs and drive innovations that promote excellence in immunology research and education. His vision is to set an ambitious course for the long-term scientific growth and fiscal vitality of the division — leading and enabling transformational research programs in cutting-edge areas of immunology. He will recruit and retain exceptional and diverse faculty, identify new and emerging areas of promise, and enable world-class discoveries.
Pasare was selected after an extensive national search chaired by Neeru Hershey, MD, PhD, director, Division of Asthma Research and co-director, Office of Pediatric Clinical Fellowships, and Paul Spearman, MD, vice chair for Clinical and Translational Research and Education.
A scientist in the Division of Immunobiology, Pasare currently serves as a professor and co-director of the Cincinnati Children’s Center for Inflammation and Tolerance. During his tenure as co-director, in partnership with Sing Sing Way, MD, PhD, the Pauline and Lawson Reed Chair in the Division of Infectious Diseases, he recruited five exceptional independent investigators to expand the current strengths of immunology at Cincinnati Children’s.
“Dr. Pasare has a robustly funded research program and is considered a world leader in understanding the communication between innate and adaptive immune systems” says Tina Cheng, MD, MPH, director of the Cincinnati Children’s Research Foundation, chair of Pediatrics at the University of Cincinnati, and chief medical officer for Cincinnati Children’s.
His research also includes topics such as microbial recognition by the innate immune system, toll-like receptor signaling and molecular mechanisms of microbial and sterile inflammation. He has more than 20 years of experience in the field of innate and adaptive immunity, the last five of which have been at Cincinnati Children’s. Pasare’s research has been published in numerous journals, including Nature, Science, Immunity, The Journal of Experimental Medicine, Nature Immunology, PNAS, Cell Reports, Journal of Immunology and Nature Communications. His work has significant implications for developing new targets against various inflammatory diseases, including autoimmunity.
After obtaining a degree in veterinary medicine, Pasare earned his PhD from the National Institute of Immunology, in New Delhi, India, and completed postdoctoral training in immunology as a Howard Hughes Medical Institute fellow at the Yale University School of Medicine. He began his independent career at the University of Texas Southwestern Medical Center in Dallas and was recruited to Cincinnati Children’s in 2018.
Pasare will be replacing David Hildeman, PhD, co-director of the Center for Transplant Immunology, who has served as interim director of the division for the past five years.
“We are grateful for Dr. Hildeman’s steady leadership and notable contributions to the division,” notes Cheng. “We are thrilled that Dr. Pasare will be building upon those successes and expanding research in other promising areas in immunobiology.”
Research Highlights from Chandrashekhar Pasare, DVM, PhD:
- Targeting RipIL-33 Pathway Could Transform Allergy Treatment
- Study to Decode Microbe-Gut Signaling Suggests Potential New Treatment For IBD
- Potential Approach Emerges to Treat Autoimmunity and Prevent Serious Side Effects of Cancer Immune Therapies
- Targeting the BCAP Protein Could Help Manage Inflammation in IBD and Infection Response
- Dendritic Cells Resist Cell Death to Prime Immune System’s Infection Response
- Newly Discovered Pathway Suggests How T-Cells Can Help Drive MS, IBD and Type 1 Diabetes